« Back to Record
Citation APA

Rao, S., Anandappa, G., Capdevila, J., Dahan, L., Evesque, L., Kim, S., Saunders, M. M., Gilbert, D. D., Jensen, L. H., Samalin, E., Spindler, K. L. G. K., Tamberi, S., Demols, A., Guren, M. M., Arnold, D., Fakih, M., Kayyal, T., Cornfeld, M., Tian, C., Catlett, M., Smith, M., & Spano, J. P. (2022). A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open, 7(4), 100529. doi:10.1016/j.esmoop.2022.100529


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/349700

Rao, S., Anandappa, G., Capdevila, J., Dahan, L., Evesque, L., Kim, S., Saunders, M. M., Gilbert, D. D., Jensen, L. H., Samalin, E., Spindler, K. L. G. K., Tamberi, S., Demols, A., Guren, M. M., Arnold, D., Fakih, M., Kayyal, T., Cornfeld, M., Tian, C., Catlett, M., Smith, M., & Spano, J. P. (2022). A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open, 7(4), 100529. doi:10.1016/j.esmoop.2022.100529